A Phase I Trial of Ipilimumab (Immunotherapy) and Imatinib Mesylate (c-Kit Inhibitor) in Patients With Advanced Malignancies
Latest Information Update: 25 Mar 2024
At a glance
- Drugs Imatinib (Primary) ; Ipilimumab (Primary)
- Indications Gastrointestinal stromal tumours; Malignant melanoma; Solid tumours
- Focus Adverse reactions
- 20 Mar 2024 Status changed from active, no longer recruiting to completed.
- 01 Sep 2023 Status changed from recruiting to active, no longer recruiting.
- 01 Aug 2022 Planned End Date changed from 28 Feb 2022 to 28 Feb 2024.